The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies

PLoS Pathogens

Volumn 9, Issue 11, 2013, Pages

  Sok, Devin ^a   Laserson, Uri ^b,c   Laserson, Jonathan ^d   Liu, Yi ^d,e   Vigneault, Francois ^c,f   Julien, Jean Philippe ^a   Briney, Bryan ^a   Ramos, Alejandra ^a,g   Saye, Karen F ^a   Le, Khoa ^a   Mahan, Alison ^b   Wang, Shenshen ^b,h   Kardar, Mehran ^b   Yaari, Gur ⁱ   Walker, Laura M ^a   Simen, Birgitte B ^j   St John, Elizabeth P ^j   Chan Hui, Po Ying ^k   Swiderek, Kristine ^k   Kleinstein, Stephen H ⁱ   Alter, Galit ^b   Seaman, Michael S ^l   Chakraborty, Arup K ^b,h   Koller, Daphne ^d   Wilson, Ian A ^a   Church, George M ^b,c   Burton, Dennis R ^a,b   Poignard, Pascal ^a,g   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Stanford University   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f AbVitro Inc   (United States)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^h Massachusetts Institute of Technology Cambridge   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j 454 Life Sciences A Roche Company   (United States)

^k Theraclone Sciences Inc   (United States)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN F (AB) FRAGMENT; NEUTRALIZING ANTIBODY; PGT121 ANTIBODY; PROTEIN VARIANT; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BINDING AFFINITY; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERROR; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SOMATIC HYPERMUTATION; VACCINATION; VIRUS NEUTRALIZATION; X RAY DIFFRACTION;

ANTIBODIES, NEUTRALIZING; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; POLYSACCHARIDES;

EID: 84888251984     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003754     Document Type: Article

References (55)

1. Kwong PD, Mascola JR, (2012) Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37: 412-425 doi:10.1016/j.immuni.2012.08.012.
2. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289 doi:10.1126/science.1178746.
3. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
4. Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817 doi:10.1126/science.1192819.
5. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
6. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593-1602 doi:10.1126/science.1207532.
7. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, et al. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334: 1097-1103 doi:10.1126/science.1213256.
8. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, et al. (2011) The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85: 4828-4840 doi:10.1128/JVI.00198-11.
9. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, et al. (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153: 126-138 doi:10.1016/j.cell.2013.03.018.
10. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, et al. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83: 757-769 doi:10.1128/JVI.02036-08.
11. Kong L, Lee JH, Doores KJ, Murin CD, Julien J-P, et al. (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20: 796-803 doi:10.1038/nsmb.2594.
12. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458: 636-640.
13. Breden F, Lepik C, Longo NS, Montero M, Lipsky PE, et al. (2011) Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS ONE 6: e16857 doi:10.1371/journal.pone.0016857.t004.
14. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193 doi:10.1084/jem.20101352.
15. Corti D, Suguitan AL, Pinna D, Silacci C, Fernandez-Rodriguez BM, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120: 1663-1673 doi:10.1172/JCI41902.
16. Frölich D, Giesecke C, Mei HE, Reiter K, Daridon C, et al. (2010) Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. J Immunol 185: 3103-3110 doi:10.4049/jimmunol.1000911.
17. Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, et al. (2011) H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE 6: e25797 doi:10.1371/journal.pone.0025797.
18. Moody MA, Yates NL, Amos JD, Drinker MS, Eudailey JA, et al. (2012) HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol 86: 7496-7507 doi:10.1128/JVI.00426-12.
19. Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, et al. (2012) High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med 4: 142ra96 doi:10.1126/scitranslmed.3003752.
20. Liao HX, Chen X, Munshaw S, Zhang R, Marshall DJ, et al. (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 208: 2237-2249 doi:10.1084/jem.20110363.
21. Liao H-X, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, et al. (2013) Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38: 176-186 doi:10.1016/j.immuni.2012.11.011.
22. Briney BS, Willis JR, Crowe JEJ, (2012) Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity. Genes and Immunity 13: 523-529 Available: http://www.ncbi.nlm.nih.gov/pubmed/22717702.
23. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2012) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098-8110 doi:10.1128/JVI.00966-10.
24. Bonsignori M, Hwang K-K, Chen X, Tsao C-Y, Morris L, et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85: 9998-10009 doi:10.1128/JVI.05045-11.
25. Ma B-J, Alam SM, Go EP, Lu X, Desaire H, et al. (2011) Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7: e1002200 doi:10.1371/journal.ppat.1002200.g010.
26. Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, et al. (2013) Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 9: e1003106.
27. Liao H-X, Lynch R, Zhou T, Gao F, Alam SM, et al. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-76 doi:10.1038/nature12053.
28. Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, et al. (2011) Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci USA 108: 20125-20129 doi:10.1073/pnas.1117531108.
29. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, et al. (2012) The development of CD4 binding site antibodies during HIV-1 infection. J Virol 86: 7588-7595 doi:10.1128/JVI.00734-12.
30. Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, et al. (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 109: 18921-18925 doi:10.1073/pnas.1214785109.
31. Edgar RC, (2010) Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26: 2460-2461 doi:10.1093/bioinformatics/btq461.
32. Zhu J, Ofek G, Yang Y, Zhang B, Louder MK, et al. (2013) Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci USA 110: 6470-5 doi:10.1073/pnas.1219320110.
33. Barak M, Zuckerman NS, Edelman H, Unger R, Mehr R, (2008) IgTree: creating Immunoglobulin variable region gene lineage trees. J Immunol Methods 338: 67-74 doi:10.1016/j.jim.2008.06.006.
34. Hastings WK, (1970) Monte Carlo sampling methods using Markov chains and their applications. Biometrika 57: 97-109.
35. Pearl J, (1982) Reverend Bayes on inference engines: A distributed hierarchical approach. Proceedings of the American Association of Artificial Intelligence National Conference on AI pp. 133-136 http://www.aaai.org/Papers/AAAI/1982/AAAI82-032.
36. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337-7348 doi:10.1128/JVI.00110-09.
37. Pancera M, Yang Y, Louder MK, Gorman J, Lu G, et al. (2013) N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. PLoS ONE 8: e55701 doi:10.1371/journal.pone.0055701.
38. Julien J-P, Sok D, Khayat R, Lee JH, Doores KJ, et al. (2013) Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 9: e1003342 doi:10.1371/journal.ppat.1003342.
39. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, et al. (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 109: E3268-E3277 doi:10.1073/pnas.1217207109.
40. Alam SM, Liao H-X, Dennison SM, Jaeger F, Parks R, et al. (2011) Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J Virol 85: 11725-11731 doi:10.1128/JVI.05680-11.
41. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, et al. (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6: e1001028 doi:10.1371/journal.ppat.1001028.
42. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071 doi:10.1126/science.1083182.
43. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343 doi:10.1038/nature10696.
44. Doores KJ, Burton DR, (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84: 10510-10521.
45. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, et al. (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489: 526-532 doi:10.1038/nature11414.
46. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348 doi:10.1126/science.1222908.
47. Moir S, Fauci AS, (2009) B cells in HIV infection and disease. Nat Rev Immunol 9: 235-245 doi:10.1038/nri2524.
48. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, et al. (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329: 112-124.
49. Kabsch W, (2010) Xds. Acta Crystallogr D Biol Crystallogr 66: 125-132 doi:10.1107/S0907444909047337.
50. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674 doi:10.1107/S0021889807021206.
51. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221 doi:10.1107/S0907444909052925.
52. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132 doi:10.1107/S0907444904019158.
53. Jones E, Oliphant T, Peterson P (2001) SciPy: Open source scientific tools for Python. http://www scipy org/.
54. Hunter JD, (2007) Matplotlib: A 2D graphics environment. Computing in Science & Engineering 9: 90-95 doi:10.1109/mcse.2007.55.
55. Ellson J, Gansner ER, Koutsofios E, North SC (2004) Graphviz and dynagraph-static and dynamic graph drawing tools. Junger M, Mutzel P, editors. Graph Drawing Software. 22 pp.